RxDoctor Payments Data

Steven Maskin, MD

Ophthalmology · Tampa, FLNPI 1124174479

Payments from drug & device makers

$63,831in general payments, 2019–2025

Across 41 payments — averaging $1556.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Katena Products, Inc. (dba Corza Medical)$53K
  • Surgical Specialties Corporation (US), Inc. (dba Corza Medical)$10K
  • Mallinckrodt Hospital Products Inc.$93
  • Sun Pharmaceutical Industries Inc.$43
  • Oyster Point Pharma, Inc.$37
  • Bausch & Lomb Americas Inc.$34
  • plus $144 from 7 others

What the payments were for

  • Royalty or licence$41,93866%
  • Speaking & faculty fees$21,54334%
  • Food & beverage$3331%
  • Education$180%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,831 in reported general payments places this provider in the 90th percentile of 1,405 ophthalmology providers in Florida.

See all ophthalmology providers in Florida

Medicare billing

Part B allowed, 2024
$112,532
Medicare patients
89
Services billed
803

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TyrvayaVarenicline Tartrate18$8,001
ValacyclovirValacyclovir Hcl14$628
Bacitracin-PolymyxinBacitracin/Polymyxin B Sulfate76$625
MoxifloxacinMoxifloxacin Hcl11$443
Doxycycline Hyclate17$278
Gentamicin Sulfate39$205

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Oyster Point Pharma, Inc.Tyrvaya$37$8,00118 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,405 ophthalmology providers in Florida.

Other ophthalmology in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →